Global Fund: Final Report of the Independent Evaluation of AMFm Phase 1

Global Fund: Final Report of the Independent Evaluation of AMFm Phase 1
The Global Fund to Fight AIDS, Tuberculosis and Malaria
4 October 2012

The Global Fund made public the final report of an independent evaluation of the pilot phase of the Affordable Medicines Facility–malaria, also known as AMFm. The report was commissioned to provide an independent evaluation to assess the extent to which AMFm has achieved the main objectives laid out for its pilot phase, which ends in December 2012. The independent evaluation was mandated by the Global Fund Board and will inform its decision in November 2012, when the Board is expected to consider the future of AMFm beyond the pilot phase.

The goal of AMFm is to improve access to artemisinin-based combination therapies (ACTs), the most effective anti-malaria treatment. The AMFm pilot phase was launched in April 2009 and began operations in July 2010. It set out to increase availability, particularly through private outlets where most people seek their treatments, and drive down the price of ACTs through a factory-gate global subsidy of ACTs combined with country-level measures to support its implementation.

The AMFm pilot phase currently operates in eight countries: Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania, and Uganda. The independent evaluation assessed the program in each of the pilot countries that was operational at the time of the endline survey.

Links to Executive Summary and Full Report here: